ArticleBMC cancer2026
Prognostic value of combined FIB-4 and AFP in predicting survival after hepatectomy for hepatocellular carcinoma: a multicenter cohort study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate prognostic assessment remains challenging in patients with hepatocellular carcinoma (HCC). Although the fibrosis-4 (FIB-4) index is widely used for non-invasive evaluation of liver fibrosis, its prognostic value in HCC remains uncertain. This study evaluates the prognostic utility of the FIB-4 index, alpha-fetoprotein (AFP), and the combined AFP-FIB-4 score for long-term survival in patients with HCC following hepatectomy.
methodsA retrospective analysis was conducted on 1174 HCC patients who underwent hepatectomy at the First People's Hospital of Changde City and Guangxi Medical University Cancer Hospital between 2014 and 2024. Survival analysis, Cox regression, and receiver operating characteristic (ROC) curve analysis were employed to assess the predictive performance of the FIB-4 index, AFP, and the combined AFP-FIB-4 score for long-term survival.
resultsMultivariate Cox regression analysis demonstrated that the FIB-4 index was not an independent predictor of disease-free survival (DFS) or overall survival (OS) in HCC patients. In contrast, AFP emerged as an independent risk factor for both DFS (HR = 1.391, 95%CI = 1.193-1.623, P < 0.001) and OS (HR = 1.267, 95%CI = 1.080-1.486, P = 0.004). Notably, the combined AFP-FIB-4 score served as a stronger independent prognostic factor for both DFS (HR = 1.404, 95% CI = 1.204-1.638, P < 0.001) and OS (HR = 1.378, 95%CI = 1.196-1.588, P < 0.001). Subgroup analysis revealed that the FIB-4 index alone failed to significantly predict prognosis in patients with Barcelona Clinic Liver Cancer (BCLC) stage B or C (P > 0.05), while AFP was ineffective in distinguishing prognosis in patients with BCLC stage 0 or A (P > 0.05). However, the AFP-FIB-4 score successfully stratified each BCLC stage subgroup into two groups with significantly different prognoses (all P < 0.05). ROC analysis demonstrated that the AFP-FIB-4 score achieved a significantly higher area under the curve (AUC 0.623) compared with AFP (AUC 0.553) and the FIB-4 index (AUC 0.565).
conclusionIncorporating AFP into the FIB-4 index enhances its prognostic performance. The AFP-FIB-4 score serves as a robust predictor of DFS and OS in HCC patients undergoing hepatectomy across different BCLC stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.